Tomohiro Tanaka
Niigata University Medical and Dental Hospital · 154 works · 3,737 citations · h-index 23
Top works
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- HLA-DR antigen expression on keratinocytes in highly inflamed parts of psoriatic lesions
- The C-terminal SH3 domain of the mouse c-Crk protein negatively regulates tyrosine-phosphorylation of Crk associated p130 in rat 3Y1 cells.
- Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.
- Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
- Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
- MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)
- Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors
- Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents
- Interstitial lung disease induced by alectinib (CH5424802/RO5424802)
- Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia
- Bivalent Ligands of CXCR4 with Rigid Linkers for Elucidation of the Dimerization State in Cells
- Population pharmacokinetics (popPK) and exposure-response (ER) analyses bridge J-ALEX to the global population with an alectinib (ALC) 600mg bid dosing regimen.
- Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
- Fluorophore Labeling Enables Imaging and Evaluation of Specific CXCR4−Ligand Interaction at the Cell Membrane for Fluorescence-Based Screening
- A future perspective on the development of chemokine receptor CXCR4 antagonists
- Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow Cytometry
- Versatile use of acid-catalyzed ring-opening of β-aziridinyl-α,β-enoates to stereoselective synthesis of peptidomimetics